A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate sleep quality in patients with mild to moderate Alzheimer's disease treated with anticholinesterase drugs in clinical practice.
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | An Observational Epidemiological Study on Evaluation of Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease in Clinical Practice |
- Sleep disturbances measures by Scores on the Pittsburgh Sleep Quality Index (PSQI) Scale [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]The PSQI consists of 19 self-rated questions which assesses sleep quality and disturbances over 1-month time interval. The 19 questions assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and the frequency and severity of specific sleep-related problems. These 19 items are grouped into seven components scores, each weighted equally on a 0-3 scale. The seven components scores are then summed to yield a global PSQI score, which has a range of 0-21; higher scores indicate worse sleep quality.
- The Level of Daytime Sleepiness determined by the Scores on the Epworth Sleepiness Scale [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]The Epworth Sleepiness Scale measures how likely, from 0 (would never take a nap) to 3 (high change of dozing), the patient is to doze off or fall asleep in common everyday situations. The scores for a total of eight questions are added together to obtain a single number. A number in the 0-9 range is considered to be normal while a number in the 10-24 range indicates that expert medical advice should be sought.
| Enrollment: | 925 |
| Study Start Date: | June 2008 |
| Study Completion Date: | July 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
This is an epidemiological (the study of health-related states or events in specific populations) study of patients with mild to moderate Alzheimer's who have been treated previously with anticholinesterase drugs (class of drugs that act in the central nervous system) up to a maximum of fifteen days. The data for each patient will be recorded on two occasions; first at a baseline visit and then at a follow-up visit at 3 months. At the baseline visit, after the patient or his/her legal representative has given written informed consent, each participating neurologist will use the study questionnaire to collect patient sociodemographic characteristics (characteristics such as age, years of education, race, sex, religion, birthplace, income, occupation, geographic location, among others), medical history and diagnosis of Alzheimer's disease. The neurologist will also record treatment for Alzheimer's disease and concomitant hypnotic medications (simultaneous use of medications that induce sleep) and evaluate the patient using two scales: the Pittsburgh Sleep Quality Index (PSQI) to record sleep disturbances and the Epworth Sleepiness Scale to determine the level of daytime sleepiness. Alzheimer treatment and concomitant hypnotic medications will be recorded again at the follow-up visit. Patient sleep quality using the PSQI and daytime sleepiness using the Epworth scale will also be evaluated again at this visit.
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients attending the neurology clinic of participating centers throughout Spain who meet eligibility criteria.
Inclusion Criteria:
- Patients with a recent diagnosis of possible or probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA criteria) within a maximum of 60 days before the baseline visit.
- Patients with mild or moderate Alzheimer's disease, defined by a Mini-Mental State Exam (MMSE) score between 11 and 25.
- Patients whose caregivers are sufficiently informed of the patients' state and if possible live with the patient.
- Patients who are capable of attending a second clinic visit with their accompanying person 3 months later, based on the clinical practice of the investigator.
- Patients and/or legal representatives who have given and signed written informed consent.
Exclusion Criteria:
- Patients who have psychotic manifestations.
- Patients who have clinically significant sleep disorder (sleep apnea syndrome, restless leg syndrome).
- Patients treated with memantine.
- Patients and/or legal representatives who refuse to give written informed consent to participate in the study.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Janssen-Cilag, S.A. |
| ClinicalTrials.gov Identifier: | NCT01478204 History of Changes |
| Other Study ID Numbers: | CR017509, GALALZ4037 |
| Study First Received: | November 21, 2011 |
| Last Updated: | October 30, 2012 |
| Health Authority: | Spain: Comité Ético de Investigación Clínica |
Keywords provided by Janssen-Cilag, S.A.:
|
Alzheimer's disease Sleep quality Anticholinesterase drugs |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders |
Mental Disorders Cholinesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013